The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II feasibility trial of a 3-week cycle of cisplatin plus radiation for post-operative high-risk head and neck cancer in a Japanese population.
N. Kiyota
No relevant relationships to disclose
M. Tahara
No relevant relationships to disclose
S. Okano
No relevant relationships to disclose
M. Kawashima
No relevant relationships to disclose
K. Matsuura
No relevant relationships to disclose
Y. Onozawa
No relevant relationships to disclose
K. Nibu
No relevant relationships to disclose
R. Hayashi
No relevant relationships to disclose
K. Yoshimura
No relevant relationships to disclose
A. Ohtsu
No relevant relationships to disclose